Amedeo Smart

Free Medical Literature Service

 

Amedeo

Alzheimer's Disease
  Free Subscription

Articles published in
Nat Med
    March 2024
  1. O'LEARY K
    A timeline of biomarker changes before Alzheimer's disease.
    Nat Med. 2024 Mar 15. doi: 10.1038/d41591-024-00018.
    >> Share

    February 2024
  2. BARTHELEMY NR, Salvado G, Schindler S, He Y, et al
    Highly Accurate Blood Test for Alzheimer's Disease Comparable or Superior to Clinical CSF Tests.
    Nat Med. 2024 Feb 21. doi: 10.1038/s41591-024-02869.
    >> Share

    January 2024
  3. JUCKER M, Walker LC
    Evidence for iatrogenic transmission of Alzheimer's disease.
    Nat Med. 2024 Jan 29. doi: 10.1038/s41591-023-02768.
    >> Share

  4. BANERJEE G, Farmer SF, Hyare H, Jaunmuktane Z, et al
    Iatrogenic Alzheimer's disease in recipients of cadaveric pituitary-derived growth hormone.
    Nat Med. 2024 Jan 29. doi: 10.1038/s41591-023-02729.
    >> Share

  5. O'LEARY K
    Modeling real-world data to repurpose drugs for Alzheimer's disease.
    Nat Med. 2024 Jan 18. doi: 10.1038/d41591-024-00003.
    >> Share

    December 2023
  6. O'LEARY K
    Positive results in Alzheimer's disease trials.
    Nat Med. 2023;29:2973.
    >> Share

    November 2023
  7. SANCHEZ VELA P, Trowbridge JJ, Levine RL
    Author Correction: Clonal hematopoiesis, aging and Alzheimer's disease.
    Nat Med. 2023 Nov 20. doi: 10.1038/s41591-023-02718.
    >> Share

    October 2023
  8. MUMMERY CJ, Borjesson-Hanson A, Blackburn DJ, Vijverberg EGB, et al
    Author Correction: Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
    Nat Med. 2023 Oct 16. doi: 10.1038/s41591-023-02639.
    >> Share

    September 2023
  9. LONGO FM, Massa SM
    Senolytic therapy for Alzheimer's disease.
    Nat Med. 2023 Sep 27. doi: 10.1038/s41591-023-02541.
    >> Share

  10. GONZALES MM, Garbarino VR, Kautz TF, Palavicini JP, et al
    Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial.
    Nat Med. 2023 Sep 7. doi: 10.1038/s41591-023-02543.
    >> Share

  11. SELF WK, Holtzman DM
    Emerging diagnostics and therapeutics for Alzheimer disease.
    Nat Med. 2023 Sep 4. doi: 10.1038/s41591-023-02505.
    >> Share

    August 2023

  12. Events in the brain during the evolution of Alzheimer's disease.
    Nat Med. 2023 Aug 7. doi: 10.1038/s41591-023-02477.
    >> Share

  13. JOHNSON ECB, Bian S, Haque RU, Carter EK, et al
    Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease.
    Nat Med. 2023 Aug 7. doi: 10.1038/s41591-023-02476.
    >> Share


  14. A fluid biomarker accurately detects tau aggregate pathology in Alzheimer's disease.
    Nat Med. 2023 Aug 2. doi: 10.1038/s41591-023-02468.
    >> Share

  15. PALMQVIST S, Rossi M, Hall S, Quadalti C, et al
    Cognitive effects of Lewy body pathology in clinically unimpaired individuals.
    Nat Med. 2023;29:1971-1978.
    >> Share

  16. QUADALTI C, Palmqvist S, Hall S, Rossi M, et al
    Clinical effects of Lewy body pathology in cognitively impaired individuals.
    Nat Med. 2023;29:1964-1970.
    >> Share

    July 2023
  17. O'LEARY K
    Putting the brakes on Alzheimer's disease.
    Nat Med. 2023 Jul 31. doi: 10.1038/d41591-023-00067.
    >> Share

  18. HORIE K, Salvado G, Barthelemy NR, Janelidze S, et al
    CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease.
    Nat Med. 2023 Jul 13. doi: 10.1038/s41591-023-02443.
    >> Share

  19. SANCHEZ VELA P, Trowbridge JJ, Levine RL
    Clonal hematopoiesis, aging and Alzheimer's disease.
    Nat Med. 2023 Jul 4. doi: 10.1038/s41591-023-02406.
    >> Share

    June 2023
  20. BOUZID H, Belk JA, Jan M, Qi Y, et al
    Clonal hematopoiesis is associated with protection from Alzheimer's disease.
    Nat Med. 2023 Jun 15. doi: 10.1038/s41591-023-02397.
    >> Share

    May 2023
  21. BELLAVER B, Povala G, Ferreira PCL, Ferrari-Souza JP, et al
    Astrocyte reactivity influences amyloid-beta effects on tau pathology in preclinical Alzheimer's disease.
    Nat Med. 2023 May 29. doi: 10.1038/s41591-023-02380.
    >> Share

  22. LJUBENKOV PA, Rabinovici GD
    Silencing tau to treat early Alzheimer's disease.
    Nat Med. 2023 May 17. doi: 10.1038/s41591-023-02357.
    >> Share

  23. LOPERA F, Marino C, Chandrahas AS, O'Hare M, et al
    Resilience to autosomal dominant Alzheimer's disease in a Reelin-COLBOS heterozygous man.
    Nat Med. 2023 May 15. doi: 10.1038/s41591-023-02318.
    >> Share

    April 2023
  24. MUMMERY CJ, Borjesson-Hanson A, Blackburn DJ, Vijverberg EGB, et al
    Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
    Nat Med. 2023 Apr 24. doi: 10.1038/s41591-023-02326.
    >> Share

    December 2022
  25. ASHTON NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, et al
    Differential roles of Abeta42/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring.
    Nat Med. 2022 Dec 1. doi: 10.1038/s41591-022-02074.
    >> Share

  26. HORIE K, Barthelemy NR, Spina S, VandeVrede L, et al
    CSF tau microtubule-binding region identifies pathological changes in primary tauopathies.
    Nat Med. 2022;28:2547-2554.
    >> Share

    November 2022
  27. MOUTINHO S
    The long road to a cure for Alzheimer's disease is paved with failures.
    Nat Med. 2022;28:2228-2231.
    >> Share

  28. OSSENKOPPELE R, Pichet Binette A, Groot C, Smith R, et al
    Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.
    Nat Med. 2022;28:2381-2387.
    >> Share


  29. Amyloid-beta and tau PET scans predict clinical progression in cognitively unimpaired people.
    Nat Med. 2022;28:2267-2268.
    >> Share

    September 2022

  30. Toward inflammation-free therapeutics in Alzheimer's disease.
    Nat Med. 2022 Sep 8. pii: 10.1038/s41591-022-01972.
    >> Share

  31. MILA-ALOMA M, Ashton NJ, Shekari M, Salvado G, et al
    Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-beta pathology in preclinical Alzheimer's disease.
    Nat Med. 2022;28:1965.
    >> Share

  32. JUNG H, Lee SY, Lim S, Choi HR, et al
    Anti-inflammatory clearance of amyloid-beta by a chimeric Gas6 fusion protein.
    Nat Med. 2022;28:1802-1812.
    >> Share

    August 2022
  33. MILA-ALOMA M, Ashton NJ, Shekari M, Salvado G, et al
    Plasma p-tau231 and p-tau217 as state markers of amyloid-beta pathology in preclinical Alzheimer's disease.
    Nat Med. 2022 Aug 11. pii: 10.1038/s41591-022-01925.
    >> Share

    July 2022
  34. SCHINDLER SE, Karikari TK
    Comorbidities confound Alzheimer's blood tests.
    Nat Med. 2022 Jul 4. pii: 10.1038/s41591-022-01875.
    >> Share

  35. MIELKE MM, Dage JL, Frank RD, Algeciras-Schimnich A, et al
    Performance of plasma phosphorylated tau 181 and 217 in the community.
    Nat Med. 2022;28:1398-1405.
    >> Share

    February 2022
  36. O'LEARY K
    Mapping the mediators of Alzheimer's disease.
    Nat Med. 2022 Feb 28. pii: 10.1038/d41591-022-00037.
    >> Share

    September 2021
  37. PASCOAL TA, Benedet AL, Ashton NJ, Kang MS, et al
    Microglial activation and tau propagate jointly across Braak stages.
    Nat Med. 2021;27:1592-1599.
    >> Share

  38. PERLMUTTER JS
    Aducanumab: look before leaping.
    Nat Med. 2021;27:1499.
    >> Share

  39. CUMMINGS J
    Why aducanumab is important.
    Nat Med. 2021;27:1498.
    >> Share

    August 2021
  40. JABBARI E, Duff KE
    Tau-targeting antibody therapies: too late, wrong epitope or wrong target?
    Nat Med. 2021;27:1341-1342.
    >> Share

    July 2021
  41. RABINOVICI GD
    Dominantly inherited Alzheimer's disease: a compass for drug development.
    Nat Med. 2021 Jul 5. pii: 10.1038/s41591-021-01434.
    >> Share

    June 2021
  42. SALLOWAY S, Farlow M, McDade E, Clifford DB, et al
    A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
    Nat Med. 2021 Jun 21. pii: 10.1038/s41591-021-01369.
    >> Share

  43. HANSSON O
    Biomarkers for neurodegenerative diseases.
    Nat Med. 2021;27:954-963.
    >> Share

    May 2021
  44. PALMQVIST S, Tideman P, Cullen N, Zetterberg H, et al
    Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures.
    Nat Med. 2021 May 24. pii: 10.1038/s41591-021-01348.
    >> Share

    April 2021
  45. VOGEL JW, Young AL, Oxtoby NP, Smith R, et al
    Four distinct trajectories of tau deposition identified in Alzheimer's disease.
    Nat Med. 2021 Apr 29. pii: 10.1038/s41591-021-01309.
    >> Share

    January 2021
  46. DUJARDIN S, Commins C, Lathuiliere A, Beerepoot P, et al
    Author Correction: Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease.
    Nat Med. 2021 Jan 29. pii: 10.1038/s41591-021-01251.
    >> Share

    November 2020
  47. ARNOLD C
    Post-hoc analysis could give new life to the Alzheimer's drug aducanumab.
    Nat Med. 2020 Nov 2. pii: 10.1038/d41591-020-00031.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016